The expected promise of CARs has been highlighted with the success of anti-CD19 CARs in ALL (acute lymphocytic leukemia) and NHL (non-Hodgkin’s lymphoma), where complete remissions have been induced in numerous patients resistant to multiple lines of chemotherapy [48,49,50,51]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.